Covid-19 roundup: J&J to ap­ply for boost­er au­tho­riza­tion this week as ad­comms are set; BioN­Tech CEO Ugur Sahin pre­dicts need for new vac­cine for­mu­la­tion

Two weeks af­ter re­leas­ing new da­ta show­ing its Covid-19 boost­er shot bumped pro­tec­tion against mod­er­ate to se­vere dis­ease up to 75% world­wide, J&J is re­port­ed­ly prepar­ing an ap­pli­ca­tion for the FDA.

The phar­ma is plan­ning on ask­ing US reg­u­la­tors ear­ly this week to au­tho­rize its Covid-19 boost­er shot, un­named sources told the New York Times. 

The FDA au­tho­rized Pfiz­er and BioN­Tech’s boost­er shot last month, and is re­port­ed­ly con­sid­er­ing a half-dose boost­er of Mod­er­na’s vac­cine. The agency put out word Fri­day that its Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee will meet on Oct. 14 and 15 to dis­cuss Mod­er­na and J&J’s boost­ers, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER